Lundbeck CEO: Alder Buy Will Boost Pipeline

 
• By Sten Stovall

Deborah Dunsire tells Scrip that buying Alder offers Lundbeck a blockbuster prevention treatment for severe migraine patients, and helps rebuild Danish group’s prospects.

Road_Sign
$1.95bn cash acquisition of Alder sees Lundbeck gain eptinezumab to treat migraines. • Source: Shutterstock

More from Deals

More from Business